Hers vs Brello: Eligibility, Cost Structure, and GLP-1 Pathway

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Welcome to the PlexusDx Education Hub, where we translate GLP-1 science, weight-management options, and the genetics beneath them into decisions you can actually use. Explore the full Peptides & GLP-1 library.

What follows is independent editorial analysis. PlexusDx runs no partnership, affiliate arrangement, or paid relationship with Hers, Brello, or their parent companies, and nothing here is sponsored.

Shoppers searching "Hers vs Brello" are usually weighing two things at once: can I qualify, and what will it cost me each month? This page treats those as the real questions. As of April 2026 the telehealth GLP-1 field holds dozens of near-identical storefronts, so we focus narrowly on how these two gate entry, how they bill, and the one variable neither intake form ever asks about.

Who gets approved: the intake gate

Every legitimate GLP-1 program begins with a screening step, and that gate is where Hers and Brello first diverge in feel rather than substance. Hers (Hims & Hers Health) runs subscription telehealth: a virtual clinical evaluation, a provider-issued prescription, and then either brand-name FDA-approved dispensing or compounded semaglutide or tirzepatide routed through a licensed compounding pharmacy. Brello (Brello Health) pairs telehealth with a compounding-pharmacy pathway. Eligibility, questionnaires, and required health history vary between them, so confirm current criteria on each brand's own site.

Two business models, one drug class

Both companies prescribe within the GLP-1 receptor agonist family. GLP-1 receptor agonists such as semaglutide, liraglutide, and dulaglutide, together with the GIP/GLP-1 dual agonist tirzepatide, act on appetite regulation, satiety signaling, and gastric emptying. The pharmacology is fixed by the molecule, not the storefront. What separates Hers from Brello is the surrounding model: dispensing route, provider structure, follow-up cadence, and how each layers fees on top of the medication.

What actually drives your monthly bill

Cost in this category is rarely a single sticker. It stacks a membership or program fee, the medication itself, and any compounded-pharmacy dispensing charge. Across the April 2026 market, total monthly spend commonly lands somewhere between roughly $200 and $700 or more, with wide swings by compound and plan. Hers and Brello each publish their own current numbers, and those numbers change often, so verify pricing directly on each brand's page before committing rather than trusting a figure quoted second-hand.

The clinical evidence under both options

Whichever brand approves you, the trial record belongs to the compound. Semaglutide for weight management was studied in the STEP program (NEJM 2021); tirzepatide in SURMOUNT (NEJM 2022); and tirzepatide for obstructive sleep apnea in SURMOUNT-OSA (NEJM 2024). Effect sizes shift with dose, compound, and population. A telehealth platform inherits that evidence base; it does not create it.

The eligibility question no form asks

Intake forms screen your history, not your biology. The genetic architecture that shapes how you sit within the GLP-1 pathway goes unmeasured. A variant in MC4R, a melanocortin receptor central to satiety and energy balance, or in FTO, the fat-mass and obesity-associated gene, describes the metabolic terrain a clinician is prescribing into, alongside GLP1R (the receptor every GLP-1 compound targets) and TCF7L2 (tied to glucose handling and GLP-1 secretion). These markers are pathway-level context; they never predict how you will respond to a specific medication.

This is where PlexusDx adds a layer neither telehealth intake captures. Before starting any protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, including the FTO, MC4R, and TCF7L2 variants that frame your baseline appetite and energy-balance biology. PlexusDx also dispenses its own Weight Management Protocols month to month, with Semaglutide Injection at $189 and Tirzepatide Injection at $289. Testing first is the test before you invest approach: it turns an intake questionnaire into an informed conversation with your provider.

No affiliation: PlexusDx has no commercial relationship with Hers or Brello and does not represent either company.

More from the Education Hub: GLP 1 Hormone and What Is GLP 1.

Disclaimer: This comparison is educational. PlexusDx is not affiliated with Hers or Brello. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways and does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Frequently Asked Questions

Do Hers and Brello have the same eligibility rules?

Not necessarily. Both screen through a provider evaluation, but each sets its own questionnaire, health-history requirements, and approval criteria. Someone cleared by one may still need extra review at the other. Check the current eligibility details on each brand's own site before assuming you qualify.

Why is the monthly cost hard to pin down?

Because the total blends a program or membership fee, the medication, and any compounding charge, and each brand adjusts those pieces often. Market totals as of April 2026 span roughly $200 to $700 or more. Confirm the live figure on the brand's pricing page rather than relying on a number quoted elsewhere.

Does the Precision Peptide Genetic Test tell me if I will qualify?

No. The test is not an eligibility tool and does not predict medication response. It maps pathway-level variants such as FTO, MC4R that describe your baseline GLP-1 and appetite biology, giving you and your clinician upstream context that applies no matter which program approves you.

Keep learning at the PlexusDx Education Hub. Return to the Peptides & GLP-1 library.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.